Catriona Reddin Galway University in Ireland and her colleagues combined results from randomized trials that have not yet been tested against placebo for a range of type 2 diabetes, which have not yet been diagnosed with dementia or cognitive impairment. They found that taking these drugs seemed to significantly reduce the risk of developing dementia or cognitive impairment during the minimum six months follow-up of the trial.
“The Gold Standard is one large randomized trial to answer this question, but this definitely adds another stream of evidence. [to past studies]”I say ziyad al-aly He is not involved in the study at Washington University School of Medicine in St. Louis, Missouri.
Reddin said the minimum six months follow-up period for the analysis was relatively short, saying “large trials need to be conducted to specifically study the effects of glucose-lowering therapy on dementia and cognitive decline.” Two clinical trials examining semaglutide as a treatment for early Alzheimer’s disease are expected to close this year.
topic:
Source: www.newscientist.com
Discover more from Mondo News
Subscribe to get the latest posts sent to your email.